New heart pump could help High-Risk patients during angioplasty
NCT ID NCT07407816
First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study tests a temporary heart pump called the Supira System in 45 people with heart failure and severe coronary artery disease who need high-risk angioplasty. The pump is inserted through a leg artery to help the heart pump blood during and after the procedure. Researchers want to see if it is safe and works well enough to avoid the need for more advanced support like a balloon pump or ECMO.
What this could mean
Our plain-language read of the trial. This is informational only, not medical advice or a prediction.
- Active substance
- Supira System (a temporary heart pump inserted through a leg artery)
- What this could lead to
- If successful, this could provide a new option to support the heart during and after high-risk angioplasty, potentially reducing complications in people with severe heart disease.
- What could go wrong
- This is a small, early feasibility study with only 45 participants, so results may not apply to everyone. The device is inserted through an artery, which carries risks like bleeding, infection, or damage to blood vessels or the heart.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Phase
-
Not a phased trial
Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.
- Participants
-
About 45 people
The number the study aims to enrol. It can still change while the study runs.
- Started
-
Oct 2025
- Expected to finish
-
May 2027
An estimate. End dates often move.
- Lead sponsor
-
A company
The lead sponsor is a pharmaceutical, biotech, or medical-device company.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
- Ages
-
18 to 90 years
- Sex
-
Anyone
- Healthy volunteers
-
Not accepted
This study is not open to healthy volunteers. The entry requirements below say who it is open to.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: * Subject has pre-existing heart failure, with NYHA Class II, III or IV prior to the index admission and documented LVEF ≤ 45% * Subject is presenting with one of the following criteria: unprotected left main coronary artery (ULMCA) disease, last patent vessel, or 3-vessel disease * Subject may benefit from hemodynamic support beyond the index procedure * Informed consent granted by the patient or legally authorized representative Exclusion Criteria: * Stroke within 6 months of the index procedure, or any prior stroke with permanent neurologic deficit * Aortic valvular disease or regurgitation categorized as moderate or greater (≥2+ on a 4-grade scale as assessed on TTE) * Aortic stenosis and/or aortic regurgitation categorized as moderate or greater (mean gradient \>20 mmHg or valve area \<1.5 cm2 as assessed on TTE) * Presence of decompensated liver disease; severe liver dysfunction (Child-Pugh Score class C) * Ongoing renal replacement therapy with dialysis or continues renal replacement therapy * Heparin-induced thrombocytopenia, current or any prior occurrences * Known hypersensitivity to intravenous contrast agents that cannot be adequately pre-medicated or known hypersensitivity to heparin, aspirin, adenosine diphosphate (ADP) receptor inhibitors, or nitinol * Known or suspected coagulopathy or abnormal coagulation parameters (defined as platelet count ≤ 100,000/mm³ or spontaneous International Normalized Ratio (INR) ≥1.5 in the absence of medication or known fibrinogen ≤1.5 g/L) * Breastfeeding or pregnant * Currently participating in active follow-up phase of another clinical study of an investigational drug or device * Other medical, social, or psychological problems that, in the opinion of the Investigator, compromises the subject's ability to provide written informed consent and/or to comply with study procedures
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Coronary arterial disease (CAD) are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
How to take part
Only the study team decides who joins. These are the ways to reach them.
-
The places running it
2 sites. The list below names each one and where it is.
-
The official record
ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.
-
A doctor treating you
A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.
Contacts and locations
Locations
-
Israeli-Georgian Medical Research Clinic HealthyCore 13g Tevdore-Mghvdeli Street Tbilisi Georgia
RECRUITINGTbilisi, Georgia
-
Tbilisi Heart and Vascular Clinic
RECRUITINGTbilisi, K'alak'i T'bilisi, 0112, Georgia
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Which SGLT2 inhibitor wins? trial pits empagliflozin against dapagliflozin
- Can daily mindful breathing ease heart failure symptoms?
- Can a smartphone app keep heart failure patients out of the hospital?
- Can VR lessons help heart patients take their medicines?
- Can better training get doctors to talk about what matters most to dying veterans?
- Can AI read heart ultrasounds as well as trained sonographers?